Loading...
Loading...
In a report published on Wednesday, PiperJaffray analyst Edward Tenthoff downgraded
Trius Therapeutics, Inc.TSRX from Overweight to Neutral and raised the price target from $11.00 to $14.82.
In the report, Tenthoff states, "We are downgrading Trius to Neutral from Overweight due to the price appreciation based on the Cubist acquisition. That said, we are increasing our price target to $14.82..."
Trius Pharmaceuticals
TSRX is currently trading at $13.62 per share.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in